

Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M283E273E87EN.html>

Date: May 2020

Pages: 36

Price: US\$ 3,500.00 (Single User License)

ID: M283E273E87EN

Abstracts

Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020

SUMMARY

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) – Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroreceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Depression, Schizophrenia, Anxiety Disorders, Cognitive Impairment, Drug Addiction, Neurodegenerative Diseases and Parkinson's Disease.

The latest report Metabotropic Glutamate Receptor 3 – Pipeline Review, H1 2020, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by

indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies
Involved in Therapeutics Development

Addex Therapeutics Ltd

Denovo Biopharma LLC

Eli Lilly and Co

Mavalon Therapeutics Ltd

Taisho Pharmaceutical Holdings Co Ltd

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles

DT-011088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3020371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGS-0274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomaglumed methionil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0650786 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones

Featured News & Press Releases

Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson's disease

Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson's disease with renewed support by The Michael J. Fox Foundation

Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglometad Methionil For Treatment Of Schizophrenia Based On Efficacy Results

Jul 11, 2012: Lilly Announces Pomaglometad Methionil Did Not Meet Primary Endpoint Of Clinical Study

Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research

Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Addex Therapeutics Ltd, H1 2020

Pipeline by Denovo Biopharma LLC, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Mavalon Therapeutics Ltd, H1 2020

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Addex Therapeutics Ltd

Denovo Biopharma LLC

Eli Lilly and Co

Mavalon Therapeutics Ltd

Taisho Pharmaceutical Holdings Co Ltd

I would like to order

Product name: Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M283E273E87EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M283E273E87EN.html>